๐Ÿ‡บ๐Ÿ‡ธ FDA

Intelligence ยท Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors โ€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ€” searchable for business development and competitive intelligence.

5,609 results for โ€œABโ€ Clear

  1. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen

    NovoThirteen

    Type 1 Diabetes

    phase 3 small molecule active

    1 trial
  2. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, insulin icodec 700 U/mL PDS290

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial
  3. Lapaquistat acetate and lipid-lowering therapy

    Takeda

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial
  4. Lapaquistat acetate and stable statin therapy

    Takeda

    Hypercholesterolemia

    phase 3 small molecule terminated

    2 trials
  5. Lebrikizumab

    Eli Lilly and Company

    Atopic Dermatitis

    phase 3 mab completed

    1 trial
  6. Lebrikizumab, MOMETASONE , Placebo for Lebrikizumab

    Eli Lilly Co.

    Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

    phase 3 small molecule active

    1 trial
  7. Lebrikizumab, Placebo for Lebrikizumab, MOMETASONE

    Eli Lilly Co.

    Perennial Allergic Rhinitis (PAR)

    phase 3 small molecule active

    1 trial
  8. Lecanemab

    Eisai Co.,

    Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia.

    phase 3 small molecule active

    1 trial
  9. Leflunomide Mylan 10 mg, filmomhulde tabletten, PLACEBO

    Disc Medicine

    polymyalgia rheumatica

    phase 3 small molecule active

    1 trial
  10. Lenabasum 20 mg

    Corbus Pharmaceuticals Holdings

    Dermatomyositis

    phase 3 small molecule completed

    1 trial
  11. Lenabasum 5 mg

    Corbus Pharmaceuticals Holdings

    Diffuse Cutaneous Systemic Sclerosis

    phase 3 small molecule terminated

    1 trial
  12. Levetiracetam XR, Masked Keppraยฎ placebo film-coated tablets (a placebo tablet inside a capsule), Keppra 500 mg film-coated tablets, Levetiracetam prolonged-release placebo granules

    NEURAXPHARM AUSTRALIA PTY LIMITED

    Refractory Partial Onset Epilepsy

    phase 3 small molecule active

    1 trial
  13. Levodopa-Carbidopa Intestinal Gel (LCIG)

    AbbVie

    Advanced Parkinson's Disease

    phase 3 small molecule completed

    1 trial
  14. Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets

    Teva Pharma GmbH

    Contraception

    phase 3 small molecule completed

    1 trial
  15. Lifestyle modification

    Takeda

    Type 2 Diabetes

    phase 3 other completed

    1 trial
  16. Lifileucel plus Pembrolizumab

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    phase 3 mab active

    1 trial
  17. Ligelizumab

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 mab completed

    1 trial
  18. Linaclotide 290 micrograms

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome Characterized by Constipation

    phase 3 small molecule completed

    1 trial
  19. Linaclotide or Matching Placebo

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation

    phase 3 small molecule completed

    1 trial
  20. Linagliptin

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    3 trials
  21. Linvoseltamab

    Regeneron UK Limited

    Multiple Myeloma

    phase 3 small molecule active

    6 trials
  22. Linvoseltamab

    Regeneron UK Limited

    Multiple Myeloma (MM)

    phase 3 small molecule active

    1 trial
  23. Linvoseltamab

    Regeneron UK Limited

    Relapsed Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    2 trials
  24. Linvoseltamab

    Regeneron UK Limited

    High Risk Smoldering Multiple Myeloma (HR-SMM)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ€“3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources